Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer-Fighting Drugs Might Also Stop Malaria Early

Published: Wednesday, August 27, 2014
Last Updated: Wednesday, August 27, 2014
Bookmark and Share
A number of compounds have been identified which could be used to fight malaria.

Scientists searching for new drugs to fight malaria have identified a number of compounds -- some of which are currently in clinical trials to treat cancer -- that could add to the anti-malarial arsenal. 

Duke University assistant professor Emily Derbyshire and colleagues identified more than 30 enzyme-blocking molecules, called protein kinase inhibitors, that curb malaria before symptoms start.

By focusing on treatments that act early, before a person is infected and feels sick, the researchers hope to give malaria – especially drug-resistant strains – less time to spread.

The findings appear online and are scheduled to appear in a forthcoming issue of the journal ChemBioChem. 

Malaria is caused by a single-celled parasite called Plasmodium that spreads from person to person through mosquito bites. When an infected mosquito bites, parasites in the mosquito’s saliva first make their way to the victim’s liver, where they silently grow and multiply into thousands of new parasites before invading red blood cells -- the stage of the disease that triggers malaria’s characteristic fevers, headaches, chills and sweats.

Most efforts to find safe, effective, low-cost drugs for malaria have focused on the later stage of the infection when symptoms are the worst. But Derbyshire and her team are testing chemical compounds in the lab to see if they can identify ones that inhibit malaria during the short window when the parasite is still restricted to the liver, before symptoms start. 

One of the advantages of her team’s approach is that focusing on the liver stage of the malaria lifecycle -- before it has a chance to multiply -- means there are fewer parasites to kill.

Using a strain of malaria that primarily infects rodents, Derbyshire and Jon Clardy of Harvard Medical School tested 1,358 compounds for their ability to keep parasites in the liver in check, both in test tubes and in mice.

“It used to be that researchers were lucky if they could identify one or two promising compounds at a time; now with advances in high-throughput screening technology we can explore thousands at once and identify many more,” said Derbyshire, an assistant professor in the Departments of Chemistry and Molecular Genetics and Microbiology at Duke.

Focusing on a particular group of enzyme-blocking compounds called protein kinase inhibitors, they identified 31 compounds that inhibit malaria growth without harming the host. Several of the compounds are currently in clinical trials to treat cancers like leukemia and myeloma.

The same compounds that stopped the stage of malaria that lurks in the liver also worked against the stage that lives in the blood.

Malaria-free mice that received a single dose before being bitten by infected mosquitos were able to avoid developing the disease altogether. 

Medicines for malaria have been around for hundreds of years, yet the disease still afflicts more than 200 million people and claims hundreds of thousands of lives each year, particularly in Asia and Africa. Part of the reason is malaria’s ability to evade attack. One of the most deadly forms of the parasite, Plasmodium falciparum, has already started to outsmart the world's most effective antimalarial drug, artemisinin, in much of southeast Asia. Infections that used to clear up in a single day of treatment now take several days.

Diversifying the antimalarial arsenal could also extend the lifespan of existing drugs, since relying less heavily on our most commonly used weapons gives the parasite fewer opportunities to develop resistance, Derbyshire said.

Another advantage is that the compounds they tested suppress multiple malaria proteins at once, which makes it harder for the parasites to develop ways around them. 

“That makes them like a magic bullet,” she said.

The research was supported by Duke University, Harvard Medical School and the National Institutes of Health (Grant Number: GM099796).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Converting Isolated Cells with Gene Editing
Researchers have used CRISPR to generate neuronal cells from isolated connective tissue.
Tuesday, August 23, 2016
Directly Reprogramming a Cell's Identity with Gene Editing
Duke engineers use CRISPR to generate neuronal cells from connective tissue.
Friday, August 12, 2016
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
Thursday, May 26, 2016
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Wednesday, May 18, 2016
Antibiotics Don't Promote Swapping of Resistance Genes
Bacterial resistance spreads through population dynamics, not an increase in gene transfers.
Wednesday, April 13, 2016
Genetic Elements that Drive Regeneration
Limb or organ regrowth may be hidden in our genes.
Friday, April 08, 2016
Immunity Genes Could Protect Some From E. Coli
When a child comes home from preschool with a stomach bug that threatens to sideline the whole family for days, why do some members of the family get sick while others are unscathed?
Monday, January 25, 2016
Travelling Salesman Uncorks Synthetic Biology Bottleneck
Computer program scrambles genetic codes for production of repetitive DNA and synthetic molecules.
Thursday, January 07, 2016
Cellular Stress Process Identified in Cardiovascular Disease
Combining the investigative tools of genetics, transcriptomics, epigenetics and metabolomics, a Duke Medicine research team has identified a new molecular pathway involved in heart attacks and death from heart disease.
Tuesday, November 10, 2015
Animals’ Genomic Buffers May Help Humans
Researchers at Duke University School of Medicine and Brigham and Women’s Hospital, Harvard Medical School have identified a mechanism that explains why some mutations can be disease-causing in one genome but benign in another.
Wednesday, July 01, 2015
New Gene Influences Apple or Pear Shape, Risk of Future Disease
Duke researchers have discovered that a gene called Plexin D1 controls both where fat is stored and how fat cells are shaped.
Tuesday, March 24, 2015
Bacterial Defense Mechanism Targets Duchenne Muscular Dystrophy
Gene therapy approach could treat 60 percent of Duchenne Muscular Dystrophy patients.
Friday, February 20, 2015
Gene Required for Recovery from Bacterial Infection Identified
Duke researchers have uncovered the genes that are normally activated during recovery from bacterial infection in the C. elegans worm. The finding could be key to new antibiotics and countering auto-immune disorders.
Monday, October 27, 2014
Cancer’s Thirst For Copper Can Be Targeted
Drugs used to block copper absorption for a rare genetic condition may find an additional use as a treatment for certain types of cancer.
Thursday, April 10, 2014
Computational Methods Identify New Alloys
Duke University researchers have used computational methods to identify dozens of previously unknown platinum-group alloys.
Monday, January 06, 2014
Scientific News
Probing How CRISPR-Cas9 Works
New study in Journal of Cell Biology examines DNA targeting dynamics in live cells.
Diagnosing Tumors of Unknown Origin
EPICUP® test is a tool that helps to identify up to 87% of cancers of unknown origin (COD).
Genome Editing Without Cleaving DNA
A team involving Kobe University researchers has succeeded in developing ‘Target-AID’, a genome editing technique that does not cleave the DNA.
New Possibilities Tumor Research
Grazer researchers say gene activity of the tumor from the analysis of circulating DNA in blood ahead.
Controlling Genome Editing with Light
New technique offers precise manipulation of when and where genes are targeted.
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Coffee Consumption Linked to Genes
Researchers have identified a gene that influences coffee consumption. The gene is thought to relate to caffeine breakdown.
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!